Restarting Elective Bariatric and Metabolic Surgery Under a Security Protocol During the COVID-19 Pandemic-a Prospective Observational Cohort Study.
Bariatric surgery
COVID-19
Obesity
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
15
01
2021
accepted:
22
03
2021
revised:
14
03
2021
pubmed:
13
4
2021
medline:
8
6
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
During the SARS-CoV-2 pandemic, in order to protect the patient and to save hospital beds, cancelation of elective surgeries has become a great challenge. Considering that obesity is a chronic disease and the possible effect imposed by quarantine on weight gain with worsening rates of obesity and metabolic comorbidities, the creation of a protocol for a safe return to bariatric surgery became essential. The aim of this study was to identify the incidence of new-onset severe acute respiratory syndrome coronavirus (SARS-CoV-2) symptoms in patients who underwent bariatric procedures during the declining curve period. Private practice METHODS: A prospective observational cohort study was conducted and included patients with indications for bariatric surgery during the decreasing curve period of the SARS-CoV-2 pandemic who underwent surgery under a hospital security protocol. Patients were asked to answer a questionnaire and had a swab PCR test for SARS-CoV-2 detection. The primary outcome measure was the presence of 14-day and 30-day postoperative symptoms associated with COVID-19. Mortality was also analyzed. Three hundred patients with negative RT-PCR were operated on from May to June 2020. Seventeen patients had their surgery postponed because of a positive RT-PCR test or close contact. None of the patients developed new-onset SARS-CoV-2 symptomatic infection after 30 days of observation. No deaths were reported. Eleven had complications not related to SARS-CoV-2. Even though this population may have a poorer outcome when infected with SARS-CoV-2, this security protocol has shown that the procedure can be safely performed during the outbreak.
Sections du résumé
BACKGROUND
During the SARS-CoV-2 pandemic, in order to protect the patient and to save hospital beds, cancelation of elective surgeries has become a great challenge. Considering that obesity is a chronic disease and the possible effect imposed by quarantine on weight gain with worsening rates of obesity and metabolic comorbidities, the creation of a protocol for a safe return to bariatric surgery became essential.
OBJECTIVE
The aim of this study was to identify the incidence of new-onset severe acute respiratory syndrome coronavirus (SARS-CoV-2) symptoms in patients who underwent bariatric procedures during the declining curve period.
SETTING
Private practice METHODS: A prospective observational cohort study was conducted and included patients with indications for bariatric surgery during the decreasing curve period of the SARS-CoV-2 pandemic who underwent surgery under a hospital security protocol. Patients were asked to answer a questionnaire and had a swab PCR test for SARS-CoV-2 detection. The primary outcome measure was the presence of 14-day and 30-day postoperative symptoms associated with COVID-19. Mortality was also analyzed.
RESULTS
Three hundred patients with negative RT-PCR were operated on from May to June 2020. Seventeen patients had their surgery postponed because of a positive RT-PCR test or close contact. None of the patients developed new-onset SARS-CoV-2 symptomatic infection after 30 days of observation. No deaths were reported. Eleven had complications not related to SARS-CoV-2.
CONCLUSIONS
Even though this population may have a poorer outcome when infected with SARS-CoV-2, this security protocol has shown that the procedure can be safely performed during the outbreak.
Identifiants
pubmed: 33844175
doi: 10.1007/s11695-021-05368-z
pii: 10.1007/s11695-021-05368-z
pmc: PMC8039500
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3083-3089Références
Lancet Diabetes Endocrinol. 2021 Jan;9(1):7-9
pubmed: 33253631
N Engl J Med. 2020 Oct 15;383(16):1535-1543
pubmed: 33053284
J Leukoc Biol. 2018 Sep;104(3):525-534
pubmed: 30066958
Br J Surg. 2020 Aug;107(9):1097-1103
pubmed: 32293715
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
Lancet Diabetes Endocrinol. 2020 Jul;8(7):640-648
pubmed: 32386567
Surg Obes Relat Dis. 2021 Jan;17(1):208-214
pubmed: 33243670
Obes Surg. 2020 Nov;30(11):4623-4626
pubmed: 32506347
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Obes Surg. 2016 Jul;26(7):1650-3
pubmed: 27107892
JAMA Surg. 2020 Aug 1;155(8):691-702
pubmed: 32530453
Surgery. 2020 Oct;168(4):572-577
pubmed: 32739140
J Surg Oncol. 2020 Dec;122(7):1293-1295
pubmed: 32786076
Surg Obes Relat Dis. 2020 Aug;16(8):981-982
pubmed: 32565394
Obes Surg. 2020 Jun;30(6):2071-2073
pubmed: 32291701
Diabetes Metab Res Rev. 2021 Feb;37(2):e3377
pubmed: 32588943
Nat Rev Endocrinol. 2020 Jul;16(7):341-342
pubmed: 32327737
Br J Surg. 2020 Jun;107(7):785-787
pubmed: 32191340
Surg Obes Relat Dis. 2016 Jan;12(1):165-70
pubmed: 26183302